alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 7

<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               SEP-30-2000
<DEBT-HELD-FOR-SALE>                                 0
<DEBT-CARRYING-VALUE>                                0
<DEBT-MARKET-VALUE>                                  0
<EQUITIES>                                  10,189,044
<MORTGAGE>                                           0
<REAL-ESTATE>                                        0
<TOTAL-INVEST>                              10,189,044
<CASH>                                         509,055
<RECOVER-REINSURE>                                   0
<DEFERRED-ACQUISITION>                               0
<TOTAL-ASSETS>                              10,728,567
<POLICY-LOSSES>                                 13,775
<UNEARNED-PREMIUMS>                                  0
<POLICY-OTHER>                                       0
<POLICY-HOLDER-FUNDS>                                0
<NOTES-PAYABLE>                                869,205
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                       183,466
<OTHER-SE>                                   6,570,929
<TOTAL-LIABILITY-AND-EQUITY>                10,728,567
<PREMIUMS>                                     171,046
<INVESTMENT-INCOME>                             54,311
<INVESTMENT-GAINS>                                   0
<OTHER-INCOME>                                       0
<BENEFITS>                                      78,263
<UNDERWRITING-AMORTIZATION>                          0
<UNDERWRITING-OTHER>                            77,027
<INCOME-PRETAX>                               (52,330)
<INCOME-TAX>                                  (21,467)
<INCOME-CONTINUING>                           (30,863)
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (30,863)
<EPS-BASIC>                                      (.17)
<EPS-DILUTED>                                    (.17)
<RESERVE-OPEN>                                  13,775
<PROVISION-CURRENT>                             13,775
<PROVISION-PRIOR>                                    0
<PAYMENTS-CURRENT>                              74,363
<PAYMENTS-PRIOR>                                     0
<RESERVE-CLOSE>                                 13,775
<CUMULATIVE-DEFICIENCY>                              0


</TABLE>
Order entered September 17, 2021

In The

Court of Appeals 

Fifth District of Texas at Dallas 

No. 05-21-00280-CR

LEWIS TERRELLE SLEDGE, Appellant

V.

THE STATE OF TEXAS, Appellee

On Appeal from the 405th District Court

Galveston County, Texas

Trial Court Cause No. 19-CR-3793

ORDER

Before the Court is the State’s appellant’s September 14, 2021 second 

motion for an extension of time to file its brief. We GRANT the motion and 

ORDER the State’s brief file on or before November 15, 2021. We DIRECT the 

Clerk to set this case at issue on November 15, 2021.

/s/ ROBERT D. BURNS, III

CHIEF JUSTICE
Exhibit 32.1
                                  ------------






               Commodore Applied Technologies, Inc. & Subsidiaries
                    Certification Of Chief Executive Officer
           Pursuant To 18 U.S.C. Section 1350, As Adopted Pursuant To
                  Section 906 Of The Sarbanes-Oxley Act Of 2002


In connection with the quarterly report of Commodore Applied Technologies, Inc.
(the "Company") on form 10-Q for the three and six-month periods ended June 30,
2004, Shelby Brewer hereby certifies, pursuant to 18 U.S.C. Section 1350, as
adopted pursuant to section 906 of the Sarbanes-Oxley Act of 2002, that to the
best of his knowledge:

         (1)  The annual report fully complies with the  requirements of section
              13(a) or 15(d) of the Securities Exchange Act of 1934; and

         (2)  The information contained in the quarterly report fairly presents,
              in all material  respects,  the financial  condition and result of
              operations of the Company.

Date:    August 12, 2004


/s/ Shelby T. Brewer
--------------------
Shelby T. Brewer
Chairman of the Board and Chief Executive Officer
1

UNITED STATES DISTRICT COURT

FOR THE DISTRICT OF COLUMBIA

GWENDOLYN HALL, )

)

Plaintiff, )

 ) Civil Action No. 1:23-cv-01908 (CRC) 

v. )

 )

CHRIS WRAY, )

)

Defendant. )

MEMORANDUM OPINION

Plaintiff initiated this civil action in the Superior Court of the District of Columbia, and 

on June 30, 2023, defendant removed the action. This matter is before the Court on its initial 

review of plaintiff’s pro se amended complaint (ECF No. 1-1). The Court will dismiss the 

complaint pursuant to 28 U.S.C. § 1915(e)(2)(B)(ii), which permits dismissal of a case “at any 

time” if the Court determines that it is frivolous. 

“A complaint must contain sufficient factual matter, accepted as true, to ‘state a claim to 

relief that is plausible on its face.’” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (quoting Bell 

Atl. Corp. v. Twombly, 550 U.S. 544, 570 (2007)). A complaint that lacks “an arguable basis 

either in law or in fact” is frivolous, Neitzke v. Williams, 490 U.S. 319, 325 (1989), and the Court 

cannot exercise subject matter jurisdiction over a frivolous complaint, Hagans v. Lavine, 415 

U.S. 528, 536-37 (1974) (“Over the years, this Court has repeatedly held that the federal courts 

are without power to entertain claims otherwise within their jurisdiction if they are ‘so attenuated 

and unsubstantial as to be absolutely devoid of merit.’”) (quoting Newburyport Water Co. v. 

Newburyport, 193 U.S. 561, 579 (1904)); Tooley v. Napolitano, 586 F.3d 1006, 1010 (D.C. Cir. 

2009) (examining cases dismissed “for patent insubstantiality,” including where plaintiff 
2

allegedly “was subjected to a campaign of surveillance and harassment deriving from uncertain 

origins.”). Consequently, a Court is obligated to dismiss a complaint as frivolous “when the 

facts alleged rise to the level of the irrational or the wholly incredible,” Denton v. Hernandez, 

504 U.S. 25, 33 (1992), or “postulat[e] events and circumstances of a wholly fanciful kind,” 

Crisafi v. Holland, 655 F.2d 1305, 1307-08 (D.C. Cir. 1981). The instant complaint satisfies this 

standard. 

Plaintiff’s amended complaint is, in a word, nonsense. Its three short paragraphs allege 

that an unidentified individual exchanged sex for marijuana, that another unidentified individual 

befriended the Mexican Mafia, and that a box of evidence was stolen from a post office in 

Sarasota, Florida, but do not manage to allege coherent facts supporting an actual legal claim. 

Because the pleading is frivolous on its face, it will be dismissed without prejudice. An Order is 

issued separately. 

CHRISTOPHER R. COOPER

DATE: July 7, 2023 United States District Judge
I 

114TH CONGRESS 

1ST SESSION H. R. 2747 

To authorize the award of a military service medal to members of the 

Armed Forces who were exposed to ionizing radiation as a result of 

participation in the testing of nuclear weapons or under other circumstances. 

IN THE HOUSE OF REPRESENTATIVES 

JUNE 12, 2015 

Mr. MCGOVERN (for himself, Mr. JONES, Mr. POMPEO, Mr. ELLISON, Ms. 

CLARK of Massachusetts, and Ms. TSONGAS) introduced the following 

bill; which was referred to the Committee on Armed Services 

A BILL 

To authorize the award of a military service medal to members of the Armed Forces who were exposed to ionizing 

radiation as a result of participation in the testing of 

nuclear weapons or under other circumstances. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Atomic Veterans Serv5 ice Medal Act’’. 


emcdonald on DSK67QTVN1PROD with BILLS
2 

•HR 2747 IH

1 SEC. 2. ATOMIC VETERANS SERVICE MEDAL. 

2 (a) SERVICE MEDAL REQUIRED.—The Secretary of 

3 Defense shall design and produce a military service medal, 

4 to be known as the ‘‘Atomic Veterans Service Medal’’, to 

5 honor retired and former members of the Armed Forces 

6 who are radiation-exposed veterans (as such term is de7 fined in section 1112(c)(3) of title 38, United States 

8 Code). 

9 (b) DISTRIBUTION OF MEDAL.— 

10 (1) ISSUANCE TO RETIRED AND FORMER MEM11 BERS.—At the request of a radiation-exposed vet12 eran, the Secretary of Defense shall issue the Atom13 ic Veterans Service Medal to the veteran. 

14 (2) ISSUANCE TO NEXT-OF-KIN.—In the case of 

15 a radiation-exposed veteran who is deceased, the 

16 Secretary may provide for issuance of the Atomic 

17 Veterans Service Medal to the next-of-kin of the per18 son. 

19 (3) APPLICATION.—The Secretary shall prepare 

20 and disseminate as appropriate an application by 

21 which radiation-exposed veterans and their next-of22 kin may apply to receive the Atomic Veterans Serv23 ice Medal. 

Æ 


emcdonald on DSK67QTVN1PROD with BILLS
# C_2022221EN.01001001.xml

| 7.6.2022 | EN | Official Journal of the European Union | C 221/10 |
| --- | --- | --- | --- |

7.6.2022

EN

Official Journal of the European Union

C 221/10

---

Prior notification of a concentration

(Case M.10782 – PLD / NBIM / SANT BOI DE LLOBREGAT ASSET)

Candidate case for simplified procedure

(Text with EEA relevance)

(2022/C 221/08)

1.

This notification concerns the following undertakings:

| — | Prologis, L.P. (‘PLD’, United States of America), |
| --- | --- |

—

Prologis, L.P. (‘PLD’, United States of America),

| — | Norges Bank Investment Management (‘NBIM’, Norway), |
| --- | --- |

—

Norges Bank Investment Management (‘NBIM’, Norway),

| — | Target Asset (Spain). |
| --- | --- |

—

Target Asset (Spain).

PLD and NBIM will acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of the whole of the Target Asset.

The concentration is accomplished by way of purchase of assets.

2.

| — | PLD owns, operates and develops real estate properties, mainly for industrial purposes, in the Americas, Europe and Asia, |
| --- | --- |

—

PLD owns, operates and develops real estate properties, mainly for industrial purposes, in the Americas, Europe and Asia,

| — | NBIM provides institutional investment for the Government Pension Fund Global on behalf of the Norwegian Ministry of Finance, focusing on worldwide investments including real estate investments in North America, Europe and Japan, |
| --- | --- |

—

NBIM provides institutional investment for the Government Pension Fund Global on behalf of the Norwegian Ministry of Finance, focusing on worldwide investments including real estate investments in North America, Europe and Japan,

| — | The Target Asset is a real estate property located in 26 Madre de Deu de Núria Street in Sant Boi de Llobregat near Barcelona in Spain, which is primarily used as a logistics facility. |
| --- | --- |

—

The Target Asset is a real estate property located in 26 Madre de Deu de Núria Street in Sant Boi de Llobregat near Barcelona in Spain, which is primarily used as a logistics facility.

3.

Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004 (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

4.

Observations must reach the Commission not later than 10 days following the date of this publication. The following reference should always be specified:

M.10782 – PLD / NBIM / SANT BOI DE LLOBREGAT ASSET

Observations can be sent to the Commission by email, by fax, or by post. Please use the contact details below:

Email: COMP-MERGER-REGISTRY@ec.europa.eu

Fax +32 22964301

Postal address:

| European Commission |
| --- |
| Directorate-General for Competition |
| Merger Registry |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

European Commission

Directorate-General for Competition

Merger Registry

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘Merger Regulation’).

1

(2)  OJ C 366, 14.12.2013, p. 5.

2

---
OSMONICS, INC. AND SUBSIDIARIES
                       VALUATION AND QUALIFYING ACCOUNTS
                                 (In thousands)

                  Years Ended December 31, 1997, 1996 and 1995

                  Column A         Column B    Column C   Column D  Column E

                                               Additions

                                    Balance Charged Charged          Balance
                                    At Beg. to Cost   to                at
                                      of      and    Other  Deduct-   End of
                                    Period  xpensed  Accts   ions     Period
                 Description

          Year Ended Dec. 31, 1997:

           Current Operations:

           Allowance for Doubtful

            Accounts                 $ 907   $ 139           $ 158    $  888

           Warranty and Start-up

            Reserve                 $1,802  $2,343          $2,245    $1,900



           Discont. Operations:

           Warranty Reserve          $1,957                 $1,957(D)    $0



          Year Ended December 31,

          1996:

           Current Operations:

           Allowance for Doubtful

            Accounts                 $1,177    $   59       $  329(A) $  907

           Warranty and Start-up

            Reserve                  $1,868    $2,414       $2,480(B) $1,802



           Discont. Operations:

           Warranty Reserve          $1,957                           $1,957


          Year Ended December 31,

          1995:

           Current Operations:

           Allowance for Doubtful

            Accounts                 $1,329   $  80  $109(C) $ 341(A) $1,177

           Warranty and Start-up

            Reserve                  $1,981  $1,406          $1,519   $1,868



           Discont. Operations:

           Allowance for Doubtful

            Accounts                  $  46                  $ 46(A)  $    0

           Warranty Reserve          $1,961                  $  4(B)  $1,957

           Reserve for   Discont.

            Operations               $  127                  $  127   $    0



          (A)       Uncollectible accounts charged against allowance.

          (B)       Actual warranty claims and start-up costs charged against

                    reserve.

          (C)       Addition due to acquisition.

          (D)       Company determined that the reserve was no longer required.
OPTICAL COATING LABORATORY, INC. AND SUBSIDIARIES
                                   EXHIBIT 11
                     COMPUTATION OF EARNINGS (LOSS) PER SHARE
                  (Amounts in thousands, except per share data)
                                        
                                             YEARS ENDED OCTOBER 31,
                                              1995    1994    1993
PRIMARY SHARES:

Average common shares outstanding             9,144   8,975   8,795
Common equivalent shares outstanding            367      48   
                                              9,511   9,023   8,795

Net income (loss)                           $ 7,391  $4,604 $(5,737)
Less dividend on preferred stock                462   

Net income (loss) applicable 
  to common stock                           $ 6,929 $ 4,604 $(5,737)

Net income (loss) per common and common
 equivalent share, primary                  $   .73 $   .51 $  (.65)

FULLY DILUTED SHARES:

Average common shares outstanding             9,144   8,975   8,795
Common equivalent shares outstanding            456      70     304
Potential dilution of preferred stock           553
                                             10,153   9,045   9,099

Net income (loss) applicable 
to common stock                             $ 6,929 $ 4,604 $(5,737)
Add back dividend on preferred stock            462

Net income (loss) for calculating 
  fully diluted earnings per share          $ 7,391  $4,604 $(5,737)

Net income (loss) per common and common
 equivalent share, fully diluted            $   .73  $  .51 $  (.63)




Note:  Fully diluted earnings (loss) per share do not result in dilution of
       three percent or more or are anti-dilutive and are, therefore, not
       separately presented in the consolidated statements of operations.
**EXHIBIT  32.2**

----

**CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO****18U.S.C. SECTION 1350, AS ADOPTED PURSUANT TOSECTION 906 OF THE SARBANES-OXLEYACT OF 2002**

In connection with the Annual Report of Applera Corporation (the “Company”) on Form 10-K for the fiscal year ended June 30, 2004, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dennis L. Winger, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

|   | (1)    | The Report        fully complies with the requirements of Section 13(a) or 15(d) of the    Securities Exchange Act of 1934; and                                   |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |                                                                                                                                                              |
|   | (2)    | The information        contained in the Report fairly presents, in all material respects, the        financialcondition and results of operations of the Company. |

 

| /s/Dennis    L. Winger           |   |
|----------------------------------|--------|
|                                  |   |
| Chief Financial    Officer  |   |

Date: September9, 2004

----
I 

114TH CONGRESS 

1ST SESSION H. R. 2785 

To suspend the issuance of visas to nationals of Brazil until such time 

as Brazil amends its laws to remove the prohibition on extradition of 

nationals of Brazil to other countries. 

IN THE HOUSE OF REPRESENTATIVES 

JUNE 15, 2015 

Mr. RYAN of Ohio (for himself and Mr. JOHNSON of Ohio) introduced the 

following bill; which was referred to the Committee on the Judiciary 

A BILL 

To suspend the issuance of visas to nationals of Brazil until 

such time as Brazil amends its laws to remove the prohibition on extradition of nationals of Brazil to other countries. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘End Immuity for Bra5 zilian Criminals Act’’. 


emcdonald on DSK67QTVN1PROD with BILLS
2 

•HR 2785 IH

1 SEC. 2. SUSPENSION OF VISAS FOR BRAZILIANS UNTIL 

2 BRAZIL AMENDS ITS LAWS TO REMOVE THE 

3 PROHIBITION ON EXTRADITION OF NATION4 ALS OF BRAZIL TO OTHER COUNTRIES. 

5 (a) SUSPENSION OF VISA ISSUANCE.—Notwith6 standing any other provision of law, no immigrant or non7 immigrant visa may be issued to a citizen, subject, na8 tional, or resident of Brazil until the President of the 

9 United States determines and certifies to the Congress 

10 that the Government of Brazil has amended its laws to 

11 remove the prohibition on extradition of nationals of 

12 Brazil to other countries. 

13 (b) WAIVER.—The President may waive the applica14 tion of subsection (a) on a case-by-case basis if the Presi15 dent determines and certifies to the Congress that it is 

16 in the national interests of the United States to do so. 

17 (c) EFFECT OF UNAUTHORIZED ISSUANCE.—Any 

18 visa issued in violation of this subsection shall be null and 

19 void. 

Æ 


emcdonald on DSK67QTVN1PROD with BILLS
# CI2022134EN.01000101.xml

| 25.3.2022 | EN | Official Journal of the European Union | CI 134/1 |
| --- | --- | --- | --- |

25.3.2022

EN

Official Journal of the European Union

CI 134/1

---

Summary of European Union decisions on marketing authorisations in respect of medicinal products of 25 March 2022

(Published pursuant to Article 13 or 38 of Regulation (EC) No 726/2004 of the European Parliament and of the Council (1))

(2022/C 134 I/01)

| — | Issuing of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted













  Date of the decision | Name of the medicinal product | INN (International Non-Proprietary Name) | Holder of the marketing authorisation | Number of the entry in the Community Register | Pharmaceutical form | ATC code (Anatomical Therapeutic Chemical Code) | Date of notification |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 25.3.2022 | EVUSHELD | tixagevimab / cilgavimab | AstraZeneca AB
  151 85 Södertälje, Sverige | EU/1/22/1651 | Solution for injection | J06BD03 | 25.3.2022 |

—

Issuing of a marketing authorisation (Article 13 of Regulation (EC) No 726/2004 of the European Parliament and of the Council): Accepted

Date of the decision

Name of the medicinal product

INN (International Non-Proprietary Name)

Holder of the marketing authorisation

Number of the entry in the Community Register

Pharmaceutical form

ATC code (Anatomical Therapeutic Chemical Code)

Date of notification

25.3.2022

EVUSHELD

tixagevimab / cilgavimab

AstraZeneca AB

151 85 Södertälje, Sverige

EU/1/22/1651

Solution for injection

J06BD03

25.3.2022

Anyone wishing to consult the public assessment report on the medicinal products in question and the decisions relating thereto is invited to contact:

| European Medicines Agency |
| --- |
| Domenico Scarlattilaan 6 |
| 1083 HS Amsterdam |
| NETHERLANDS |

European Medicines Agency

Domenico Scarlattilaan 6

1083 HS Amsterdam

NETHERLANDS

---

(1)  OJ L 136, 30.4.2004, p. 1.

---